Please assess the completion status of the following clinical trial:

Trial Title: A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic breast cancer~* Eastern Cooperative Oncology Group (ECOG) 0 or 1~* HER2-expressing primary or metastatic tumor~* Recurrence within 1 year completing adjuvant trastuzumab OR rapid progress following first-line trastuzumab-based care.~* Measurable disease with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1~* Normal organ function, including bone marrow function, renal function, liver function, and cardiac function~* Signed and dated an informed consent form~* Life expectancy of at least 12 weeks~Exclusion Criteria:~* Pregnant or breast feeding~* left ventricular ejection fraction (LVEF) \< 45% by echocardiogram~* Disease-free interval (DFI) less than 12 months~* Uncontrolled medical problems~* Any previous malignancy exceptions for carcinoma of the cervix, squamous carcinoma of the skin, or basal cell carcinoma of the skin~* Patients were unable or unwilling to comply with program requirements

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lapatinib and Capecitabine or Vinorelbine (Type: EXPERIMENTAL): Lapatinib 1250mg qd and Capecitabine 1000mg/m2 bid or Vinorelbine 25mg/m2 iv (d1,d8)

Based on this trial design, predict the completion outcome and termination type (if applicable).